Rifampicin News and Research RSS Feed - Rifampicin News and Research

Xpert MTB/RIF test quickly detects TB and resistance to rifampicin

A second systematic review of a diagnostic test for tuberculosis (TB) endorsed by the World Health Organisation (WHO), has confirmed the accuracy of the test. The updated review assessing the accuracy of Xpert MTB/RIF includes new studies published since the original Cochrane Review was published in January last year. [More]
Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Sovaldi (sofosbuvir) 400 mg tablets, a once-daily oral nucleotide analogue polymerase inhibitor for the treatment of chronic hepatitis C infection in adults, in combination with other antiviral agents (ribavirin and pegylated interferon alpha (peg-IFN)). [More]

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Vitekta (elvitegravir 85 mg and 150 mg) tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known mutations associated with resistance to elvitegravir. [More]
Groundbreaking study reveals novel approach to treat, eliminate MRSA infection

Groundbreaking study reveals novel approach to treat, eliminate MRSA infection

Recent work from University Distinguished Professor of Biology Kim Lewis promises to overcome one of the leading public health threats of our time. In a groundbreaking study published Wednesday in the journal Nature, Lewis' team presents a novel approach to treat and eliminate methicillin resistant staphylococcus aureus, or MRSA, a potent bacterium whose resistance to antibiotics has kept it one step ahead of researchers. [More]
TB Alliance, Svizera Europe partner to create, enable access to new medicines for childhood TB

TB Alliance, Svizera Europe partner to create, enable access to new medicines for childhood TB

In an effort to develop and deliver treatments for children with tuberculosis—answering a critical need in public health today—TB Alliance, a not-for-profit organization with the mission to develop better, faster-acting, and affordable drugs for TB, has entered into a collaboration with Svizera Europe, one of the leading global supply and distribution companies for TB treatments. [More]
Holistic approach to understand and treat TB

Holistic approach to understand and treat TB

For years, physicians around the world have watched as strain after strain of the deadly bacteria Mycobacterium tuberculosis evolves resistance to drugs. [More]
Vitamin C kills drug-resistant TB bacteria in lab

Vitamin C kills drug-resistant TB bacteria in lab

In a striking, unexpected discovery, researchers at Albert Einstein College of Medicine of Yeshiva University have determined that vitamin C kills drug-resistant tuberculosis bacteria in laboratory culture. [More]
Multidrug-resistant tuberculosis (MDR-TB): an interview with Dr. Jennifer Cohn, Médecins Sans Frontières

Multidrug-resistant tuberculosis (MDR-TB): an interview with Dr. Jennifer Cohn, Médecins Sans Frontières

MDR-TB is tuberculosis, a mycobacterial infection, that has developed resistance to two important and powerful first-line anti-TB drugs, INH and rifampin. [More]
Tiny proteins prevent bacterial gene transcription

Tiny proteins prevent bacterial gene transcription

In the search for new antibiotics, researchers are taking an unusual approach: They are developing peptides, short chains of protein building blocks that effectively inhibit a key enzyme of bacterial metabolism. [More]

Steroids used for treating TB may reduce death rates from all types of TB

The routine use of steroids to treat tuberculosis may help reduce deaths from all types of the disease, according to a new review of existing research. [More]
Improving tuberculosis (TB) diagnosis: an interview with Professor Madhukar Pai, MD, PhD

Improving tuberculosis (TB) diagnosis: an interview with Professor Madhukar Pai, MD, PhD

TB is an infectious disease caused by Mycobacterium tuberculosis. Nearly 9 million people develop TB every year, and TB kills nearly 1.4 million individuals each year. While the incidence of TB has steadily declined in the west, it remains a huge public health problem in many developing countries, with India having the highest burden. [More]

Xpert diagnosis of TB and its drug resistant strains

The use of a novel, diagnostic test called Xpert is both sensitive and specific in detecting tuberculosis and rifampicin resistance, report US researchers. [More]
TB test offers rapid detection of TB and drug-resistant strains according to new study

TB test offers rapid detection of TB and drug-resistant strains according to new study

A diagnostic test for tuberculosis (TB) can accurately and quickly detect both TB and drug-resistant strains, according to a new study. The authors of a new systematic review assessing the diagnostic accuracy of the Xpert® MTB/RIF test published in The Cochrane Library say their study can provide timely advice for clinicians and policymakers in countries where TB is a major public health problem. [More]

High-dose rifampicin combination could improve meningitis survival

A treatment regimen including high-dose rifampicin administered intravenously in addition to standard or high-dose moxifloxacin has an acceptable safety profile and could improve survival for patients with tuberculous meningitis, indicate phase II trial results. [More]

Infectex initiates enrollment in SQ109 Phase IIb-III trial for MDR-TB

Infectex, a Russian biotech company in Maxwell Biotech Venture Fund's portfolio, announced today enrollment of the first patients in its Phase IIb-III clinical trial of SQ109 for MDR-TB. Infectex was founded in 2011 to develop and commercialize innovative products for the treatment of TB. [More]
Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated. [More]
Intensified antibiotic treatment can improve prognosis of patients with TB meningitis

Intensified antibiotic treatment can improve prognosis of patients with TB meningitis

Researchers from the Radboud UMC have conducted the first study globally to show that intensified antibiotic treatment can improve the prognosis of patients with tuberculous (TB) meningitis, the most severe form of TB which carries a mortality of up to 50%. [More]

Sanofi, TB Alliance form research collaboration to search for new treatment compounds

French drug maker Sanofi on Thursday announced a new three-year research collaboration agreement with the TB Alliance "to accelerate the discovery and development of novel compounds against tuberculosis," RTTNews reports. [More]
TB Alliance, Sanofi partner to discover and develop novel compounds against tuberculosis

TB Alliance, Sanofi partner to discover and develop novel compounds against tuberculosis

Sanofi and the Global Alliance for TB Drug Development announced today a new research collaboration agreement to accelerate the discovery and development of novel compounds against tuberculosis (TB), a deadly infectious disease that resulted in almost 1.5 million deaths worldwide in 2010. [More]
Natural antibiotic to treat tuberculosis

Natural antibiotic to treat tuberculosis

A natural product secreted by a soil bacterium shows promise as a new drug to treat tuberculosis report scientists in a new study published in EMBO Molecular Medicine. A team of scientists working in Switzerland has shown how pyridomycin, a natural antibiotic produced by the bacterium Dactylosporangium fulvum, works. [More]